Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 61 results for "Mk 5172"

No Evidence of Pharmacokinetic Drug-Drug Interaction in Health...

EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria april 22-26 Reported by Jules Levin EASL 2015 April 22-26 Vienna Austria William L. Marshall*1; Wendy W. National AIDS Treatment Advocacy Project, 2 weeks ago
Seeking Alpha

Gilead, Merck And Achillion/J&J Square Off In An HCV 'Nuc'lear Showdown

12:33 PM ET | About: Gilead Sciences, Inc. (GILD), Includes: ACHN, JNJ, MRK by: Small Pharma Analyst Summary Comparison of 7-day monotherapy of Sovaldi vs MK-3682 (MRK) and ACH 3422 indicate a rate of viral clearance of Sovaldi > MK-3682 > ...
 Seeking Alpha1 day ago Gilead's Predicament: Revenue And Earnings Are Unsustainable  Seeking Alpha3 weeks ago
Advance For NPs And PAs

Fitch: More Competitors Expected in the Hepatitis C and Cardiovascular Markets

NEW YORK & CHICAGO--(BUSINESS WIRE)-- An ongoing stream of clinical data pointing to good safety and efficacy for new hepatitis C therapies indicates that competition for the drugs made by Gilead and AbbVie will increase, according to Fitch Ratings' ...
 CNBC1 week ago New Hepatitis C Therapies  Advance For NPs And PAs1 month ago

Dubious IP Makes Achillion Pharma A Stock To Avoid

May. 13, 2015 11:58 AM ET | About: Achillion Pharmaceuticals, Inc. (ACHN), Includes: GILD, MRK by: Small Pharma Analyst Summary Achillion (ACHN) has the only unpartnered HCV NS5B nucleoside, ACH 3422. Achillion's patent application ...
 Seeking Alpha1 week ago

Merck Seems Confident About New Launches

As expected, Merck s (NYSE:MRK) revenues declined during the first quarter of 2015. This was partially due to strengthening dollar and partially due to the impact of divestitures and competitive pressure. The company's cardiovascular division's ...
 Trefis2 weeks ago Merck & Co. (MRK) Can't Catch a Break for Sugammadex, Faces Third FDA Rejection 3/17/2015  ClinicSpace2 months ago

Awards for March 2015

Federal Awards Adinoff, Bryon, NIH, Lidocaine as a Treatment for Cocaine Relapse and Craving, $195,768; Bai, Xiaoying, NIH, Role of Transcription Pausing in Hematopoietic Stem Cell Development, $354,487; Banerjee, Subhash, UT Arlington/NIH, Novel ...
 University of Texas2 weeks ago

Merck Phase 3 clinical trials evaluating grazoprevir/elbasvir, C-EDGE program,

Primary results from the C-EDGE program, Phase 3 clinical trials evaluating grazoprevir/elbasvir (with and without ribavirin) across multiple HCV genotypes (1, 4 and 6) and diverse patient populations, including those difficult to treat, over a ...
 National AIDS Treatment Advocacy Project3 weeks ago

Once-daily grazoprevir/elbasvir is effective and well-tolerated in patients infected with chronic hepatitis C virus

Results presented at The International Liver Congress 2015 show that a 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir (GZR/EBR) is effective and well-tolerated in treatment-naive (TN) patients infected with chronic hepatitis C ...
 Medical News Today3 weeks ago

VIDEO: C-SURFER: Patients with kidney disease, HCV achieve high rates of SVR

VIENNA — Howard Monsour Jr., MD, chief of hepatology, Houston Methodist Hospital, Texas, discussed results of the C-SURFER trial, where 99% of patients with advanced chronic kidney disease treated with grazoprevir and elbasvir for chronic ...
 Orthopedics Today3 weeks ago

C-SWIFT: 8 weeks of therapy may be possible with grazoprevir/elbasvir

VIENNA — Patients with cirrhosis as well as genotype 1 and genotype 3 HCV responded favorably to 8 weeks of treatment with a novel grazoprevir and elbasvir-based combination regimen, according to findings presented at the 2015 International Liver ...
 Orthopedics Today3 weeks ago C-EDGE: Grazoprevir/elbasvir regimen yields high SVR rates in patients with HCV  Orthopedics Today4 weeks ago C-SALT: Child-Pugh B patients responded to grazoprevir/elbasvir  Orthopedics Today4 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less